Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression (TRD-BIOTMS)
Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments. Intermittent theta burst stimulation (iTBS), a non-invasive neuromodulation technique targeting the left dorsolateral prefrontal cortex, has emerged as an effective treatment option for these patients. However, the biological mechanisms underlying treatment response remain poorly understood.
This single-center, prospective, investigator-initiated clinical study aims to investigate the effects of iTBS on clinical symptoms, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with treatment-resistant depression.
Fifty patients with treatment-resistant depression and fifty healthy control participants will be enrolled. Patients will receive active iTBS treatment for four weeks (20 sessions), while healthy controls will undergo baseline clinical, cognitive, and biological assessments without receiving any intervention.
Clinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test, Trail Making Test A and B, and verbal fluency tests.
Peripheral blood samples will be collected before and after treatment to measure inflammatory, neuroplasticity, and neuroprotective biomarkers, including IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2). Gene expression analyses will also be performed using quantitative polymerase chain reaction (qPCR).
The study aims to identify biological mechanisms associated with iTBS treatment response and to explore potential biomarkers that may predict clinical improvement in patients with treatment-resistant depression. The findings may contribute to the development of personalized neuromodulation strategies and biomarker-guided treatment approaches for depression.
研究概览
详细说明
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder associated with substantial functional impairment, reduced quality of life, increased suicide risk, and significant socioeconomic burden. Despite the availability of pharmacological, psychotherapeutic, and neuromodulation-based treatments, a considerable proportion of patients fail to achieve adequate clinical improvement and develop treatment-resistant depression (TRD).
Treatment-resistant depression is commonly defined as inadequate response to at least two antidepressant medications administered at adequate doses and durations. Patients with TRD frequently experience chronic symptoms, recurrent episodes, impaired psychosocial functioning, increased healthcare utilization, and poorer long-term outcomes.
Intermittent theta burst stimulation (iTBS) has emerged as an effective, non-invasive neuromodulation treatment for TRD. Compared with conventional high-frequency repetitive transcranial magnetic stimulation (rTMS), iTBS offers substantially shorter treatment sessions while maintaining comparable efficacy. However, the biological mechanisms underlying treatment response remain incompletely understood, and reliable biomarkers predicting therapeutic outcomes have not yet been established.
Accumulating evidence suggests that neuroinflammation, impaired neuroplasticity, oxidative stress, and altered immune regulation contribute to the pathophysiology of depression and may influence treatment response. Therefore, investigating biological changes associated with iTBS may improve the understanding of therapeutic mechanisms and facilitate the development of personalized treatment strategies.
This single-center, prospective, investigator-initiated clinical study aims to comprehensively evaluate clinical outcomes, executive functions, and peripheral inflammatory and neuroprotective biomarkers in patients with TRD receiving iTBS treatment.
A total of 100 participants will be enrolled, including 50 patients with treatment-resistant depression and 50 healthy controls. Patients will receive active iTBS over the left dorsolateral prefrontal cortex using a MagVenture X100 device for 20 sessions administered over four weeks. Healthy controls will not receive any intervention and will participate only in baseline assessments.
Clinical outcomes will be evaluated using the 17-item Hamilton Depression Rating Scale (HAM-D-17), Patient Health Questionnaire-9 (PHQ-9), Clinical Global Impression (CGI), and Insomnia Severity Index (ISI). Executive functions will be assessed using the Wisconsin Card Sorting Test (WCST), Trail Making Test A and B (TMT-A and TMT-B), and verbal fluency tests.
Peripheral blood samples will be collected before and after treatment. Serum levels of IL-1β, IL-6, IL-10, TNF-α, high-sensitivity C-reactive protein (hs-CRP), brain-derived neurotrophic factor (BDNF), apolipoprotein D (APOD), serum amyloid A1 (SAA1), and serum amyloid A2 (SAA2) will be measured using enzyme-linked immunosorbent assays (ELISA). Gene expression analyses of relevant biomarkers will be performed using quantitative polymerase chain reaction (qPCR).
The primary outcome will be the change in HAM-D-17 scores from baseline to week 4. Secondary outcomes will include changes in clinical scales, executive function performance, biomarker levels, and gene expression profiles. Associations between biological markers, cognitive performance, and treatment response will also be examined.
The study seeks to identify potential biomarker signatures associated with iTBS response and contribute to the development of biomarker-guided, personalized neuromodulation strategies for treatment-resistant depression.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:BEYAZIT GARİP, Principal Investigator
- 电话号码:+903123044512
- 邮箱:beyazitgarip@gmail.com
学习地点
-
-
-
Ankara、土耳其(türkiye)、06000
- 招聘中
- Gulhane Training and Research Hospital
-
接触:
- Dr.Beyazıt Garip
- 电话号码:03122977975
- 邮箱:beyazitgarip@gmail.com
-
-
Ankara
-
Ankara、Ankara、土耳其(türkiye)、06000
- 尚未招聘
- Gulhane Training and Research Hospital
-
接触:
- BEYAZIT GARİP, Principal Investigator
- 电话号码:03123044512
- 邮箱:beyazitgarip@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria
Treatment-Resistant Depression Group:
Age between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations.
Eligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol.
Healthy Control Group:
Age between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments.
Exclusion Criteria
Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders.
History of epilepsy, brain tumor, severe head trauma, or significant neurological disease.
Any contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices.
Active infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years.
Previous intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active iTBS Treatment
Participants with treatment-resistant depression will receive active intermittent theta burst stimulation (iTBS) over the left dorsolateral prefrontal cortex using a MagVenture X100 device.
Treatment will be administered at 90% of the resting motor threshold, with 1800 pulses per session, 5 sessions per week, for a total of 20 sessions over 4 weeks.
Participants will continue their routine pharmacological treatments throughout the study.
Clinical assessments, neuropsychological testing, and peripheral biomarker analyses will be performed before and after treatment.
|
Intermittent theta burst stimulation (iTBS) will be administered over the left dorsolateral prefrontal cortex using a CE-marked MagVenture X100 transcranial magnetic stimulation device.
Stimulation intensity will be set at 90% of each participant's resting motor threshold.
The protocol will consist of bursts of three pulses delivered at 50 Hz, repeated at a frequency of 5 Hz, with 2-second stimulation trains followed by 8-second intertrain intervals.
Participants will receive 1800 pulses per session, five sessions per week, for a total of 20 sessions over four weeks (36,000 pulses in total).
Participants will continue their routine pharmacological treatments throughout the study, and no investigational medicinal products will be initiated as part of the research protocol.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Hamilton Depression Rating Scale (HAM-D-17) Total Score
大体时间:Baseline and Week 4
|
The primary outcome is the change in the 17-item Hamilton Depression Rating Scale (HAM-D-17) total score between baseline and week 4 following intermittent theta burst stimulation (iTBS) treatment.
Clinical response will be defined as a reduction of 50% or greater from baseline, and remission will be defined as a HAM-D-17 total score of 7 or lower.
|
Baseline and Week 4
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Patient Health Questionnaire-9 (PHQ-9) Score
大体时间:Baseline and Week 4
|
Change in depressive symptom severity measured by the Patient Health Questionnaire-9 (PHQ-9) following iTBS treatment.
|
Baseline and Week 4
|
|
Change in Insomnia Severity Index (ISI) Score
大体时间:Baseline and Week 4
|
Change in insomnia severity following iTBS treatment.
|
Baseline and Week 4
|
|
Change in Wisconsin Card Sorting Test Performance
大体时间:Baseline and Week 4
|
Change in executive function performance assessed using the Wisconsin Card Sorting Test
|
Baseline and Week 4
|
|
Change in Peripheral Inflammatory Biomarker Levels
大体时间:Baseline and Week 4
|
Change in IL-1β, IL-6, IL-10, TNF-α, and high-sensitivity C-reactive protein (hs-CRP) levels following iTBS treatment.
|
Baseline and Week 4
|
|
Change in Neuroprotective Biomarker Levels
大体时间:Baseline and Week 4
|
Change in BDNF, APOD, SAA1, and SAA2 levels following iTBS treatment
|
Baseline and Week 4
|
|
Change in Gene Expression Profiles
大体时间:Baseline and Week 4
|
Change in gene expression levels of inflammatory and neuroprotective biomarkers measured by quantitative polymerase chain reaction (qPCR).
|
Baseline and Week 4
|
合作者和调查者
出版物和有用的链接
一般刊物
- Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16.
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26.
- Fyfe-Desmarais G, Desmarais F, Rassart E, Mounier C. Apolipoprotein D in Oxidative Stress and Inflammation. Antioxidants (Basel). 2023 Apr 28;12(5):1027. doi: 10.3390/antiox12051027.
- Lee H, Rhee SJ, Kim J, Lee Y, Kim H, Lee J, Lee K, Shin H, Kim H, Lee TY, Kim M, Kim EY, Kim SH, Ahn YM, Kwon JS, Han D, Ha K. Plasma proteomic data in bipolar II disorders and major depressive disorders. Data Brief. 2021 Oct 17;39:107495. doi: 10.1016/j.dib.2021.107495. eCollection 2021 Dec.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- GULHANE-TRD-TMS-BIOMARKER-2026
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 国际碳纤维联合会
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.